NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → [Urgent] Protect your money before November (From Weiss Ratings) (Ad) Free CYTK Stock Alerts $51.99 -0.79 (-1.50%) (As of 04:14 PM ET) Add Compare Share Share Today's Range$51.57▼$53.4450-Day Range$47.86▼$75.0552-Week Range$25.98▼$110.25Volume781,704 shsAverage Volume2.72 million shsMarket Capitalization$5.45 billionP/E RatioN/ADividend YieldN/APrice Target$76.41 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside46.7% Upside$76.41 Price TargetShort InterestBearish14.86% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.66Based on 24 Articles This WeekInsider TradingSelling Shares$7.89 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.55) to ($4.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector156th out of 913 stocksPharmaceutical Preparations Industry65th out of 430 stocks 4.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.86% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Cytokinetics has recently increased by 15.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 3.1 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Cytokinetics this week, compared to 8 articles on an average week.Search Interest11 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat Follows4 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,892,234.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders.Read more about Cytokinetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.55) to ($4.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -9.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -9.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesJune 18 at 5:42 AM | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) Director B Lynne Parshall Sells 5,000 SharesJune 12, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 7,788 SharesJune 18, 2024 | Weiss Ratings (Ad)[Urgent] Protect your money before NovemberDo you feel like something strange is happening in America? Every day, hundreds of thousands of military-aged men are pouring through our broken borders … I share all the details about what's happening, and give you the three steps I feel you must take to prepare yourself — RIGHT NOW.June 12, 2024 | insidertrades.comMuna Bhanji Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockJune 8, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 22,500 SharesJune 6, 2024 | insidertrades.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 1,580 Shares of StockJune 4, 2024 | insidertrades.comRobert Wong Sells 13,011 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockJune 18 at 7:08 AM | americanbankingnews.comShort Interest in Cytokinetics, Incorporated (NASDAQ:CYTK) Grows By 15.7%June 18, 2024 | Weiss Ratings (Ad)[Urgent] Protect your money before NovemberDo you feel like something strange is happening in America? Every day, hundreds of thousands of military-aged men are pouring through our broken borders … I share all the details about what's happening, and give you the three steps I feel you must take to prepare yourself — RIGHT NOW.June 18 at 6:34 AM | americanbankingnews.comShort Interest in Cytokinetics, Incorporated (NASDAQ:CYTK) Expands By 15.7%June 18 at 2:52 AM | americanbankingnews.comCytokinetics' (CYTK) Buy Rating Reaffirmed at HC WainwrightJune 17 at 7:30 AM | globenewswire.comCytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese ParticipantsJune 9, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells $1,099,125.00 in StockJune 8, 2024 | americanbankingnews.comB. Riley Weighs in on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)June 4, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2024 | globenewswire.comCytokinetics to Participate in June Investor ConferencesMay 28, 2024 | globenewswire.comCytokinetics Announces Closing of Public Offering of Common StockMay 28, 2024 | markets.businessinsider.comBuy Rating Justified for Cytokinetics Amid Strong Capital Position and Promising Drug PipelineMay 27, 2024 | finance.yahoo.comIs Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?May 26, 2024 | uk.investing.comCytokinetics shares target cut, cites key financial transactionsMay 24, 2024 | seekingalpha.comCytokinetics Decides To Go It AloneMay 23, 2024 | markets.businessinsider.comCytokinetics: Strong Buy Rating Backed by Significant Financial Support and Promising PipelineMay 23, 2024 | msn.comWhy Cytokinetics (CYTK) Shares Are FallingMay 23, 2024 | marketwatch.comCytokinetics Shares Drop 17% After Public Offering PricesMay 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Soleno Therapeutics (SLNO)May 22, 2024 | globenewswire.comCytokinetics Announces Pricing of Public Offering of Common StockMay 22, 2024 | globenewswire.comCytokinetics Announces Proposed Public Offering of Common StockSee More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/18/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$76.41 High Stock Price Target$106.00 Low Stock Price Target$50.00 Potential Upside/Downside+44.8%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($5.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-14,141.74% Pretax Margin-14,141.74% Return on EquityN/A Return on Assets-67.32% Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio7.19 Sales & Book Value Annual Sales$7.53 million Price / Sales734.92 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-13.40Miscellaneous Outstanding Shares104,850,000Free Float101,289,000Market Cap$5.53 billion OptionableOptionable Beta0.75 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President, Principal Financial Officer & Director Comp: $1.33MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Comp: $752.84kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsAvidity BiosciencesNASDAQ:RNAConstellation PharmaceuticalsNASDAQ:CNSTZogenixNASDAQ:ZGNXIntercept PharmaceuticalsNASDAQ:ICPTPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsRobert I BlumSold 22,500 sharesTotal: $1.18 M ($52.60/share)B Lynne ParshallSold 5,000 sharesTotal: $262,750.00 ($52.55/share)Fady Ibraham MalikSold 7,788 sharesTotal: $413,075.52 ($53.04/share)Muna BhanjiSold 2,000 sharesTotal: $104,140.00 ($52.07/share)Robert I BlumSold 22,500 sharesTotal: $1.10 M ($48.85/share)View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 17 analysts have issued 1-year price objectives for Cytokinetics' shares. Their CYTK share price targets range from $50.00 to $106.00. On average, they expect the company's share price to reach $76.41 in the next twelve months. This suggests a possible upside of 46.7% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 at the beginning of the year. Since then, CYTK shares have decreased by 37.6% and is now trading at $52.07. View the best growth stocks for 2024 here. Are investors shorting Cytokinetics? Cytokinetics saw a increase in short interest in May. As of May 31st, there was short interest totaling 16,420,000 shares, an increase of 15.7% from the May 15th total of 14,190,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is presently 7.2 days. Currently, 14.9% of the company's stock are sold short. View Cytokinetics' Short Interest. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) issued its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.16) by $0.17. The biopharmaceutical company had revenue of $0.84 million for the quarter, compared to analyst estimates of $0.91 million. The business's revenue was down 81.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.38) earnings per share. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), Fidelity Disruptive Medicine ETF (FMED), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and Vanguard Russell 2000 Growth ETF (VTWG). What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.56%), Price T Rowe Associates Inc. MD (2.80%), HAP Trading LLC (0.00%), Janus Henderson Group PLC (0.76%), Westfield Capital Management Co. LP (0.70%) and Hood River Capital Management LLC (0.66%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert Arthur Harrington, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
